Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lytix Biopharma AS ( (DE:6BG) ) has issued an announcement.
Lytix Biopharma will present final Phase II results from its ATLAS-IT-05 study of ruxotemitide (LTX-315) in combination with pembrolizumab at the AACR Annual Meeting 2026 in San Diego, underscoring growing scientific interest in intratumoral oncolytic approaches. The trial enrolled patients with unresectable advanced or metastatic melanoma who had progressed after anti-PD-1 or anti-PD-L1 therapy, and the company says the data further support ruxotemitide’s potential to trigger anti-tumor immune responses in this hard-to-treat population.
The poster, to be presented by melanoma immunotherapy expert Dr. Adi Diab of Cleveland Clinic, will detail outcomes in checkpoint-refractory melanoma and may help position ruxotemitide as a complementary agent to checkpoint inhibitors. By disrupting tumor cells locally and potentially converting immunologically “cold” tumors into “hot” ones, ruxotemitide could enhance responses to existing immunotherapies, a development that, if confirmed by the data, would be significant for both Lytix’s pipeline prospects and the broader immuno-oncology field.
Following the conference, Lytix plans to make the poster publicly available on its website, broadening access to the study’s findings for clinicians, researchers and investors. The visibility at a major cancer research forum may strengthen Lytix’s profile in the competitive immuno-oncology space and inform future clinical development strategies for ruxotemitide and related oncolytic molecules.
More about Lytix Biopharma AS
Lytix Biopharma AS, based in Oslo, Norway, is a clinical-stage immuno-oncology biotech developing novel intratumoral oncolytic peptide therapies for cancer. Its lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule aimed at inducing durable anti-cancer immunity across multiple tumor types, with applications as both monotherapy and in combination regimens, and is listed on Euronext Growth Oslo under the ticker LYTIX.
Average Trading Volume: 57,200
Current Market Cap: NOK815.1M
Find detailed analytics on 6BG stock on TipRanks’ Stock Analysis page.